Key result
Aspirin thromboprophylaxis following total hip arthroplasty was associated with similar 90-day all-cause mortality (p=0.780) and venous thromboembolism (p=1) compared to enoxaparin and warfarin.
Why the study?
Following implementation of a risk-stratified protocol utilizing aspirin as standard, the authors sought to evaluate standard use of aspirin on fatal pulmonary embolism, all-cause mortality, and venous thromboembolism after total hip arthroplasty.
Does aspirin monotherapy prevent fatal pulmonary embolism, all-cause mortality, and VTE compared to enoxaparin or warfarin in patients following total hip arthroplasty?
Population
4204 elective THAs
Comparison
Aspirin vs enoxaparin vs warfarin
Design
Retrospective review of a consecutive series
Follow-up
90 postoperative days
Authors
Loading...
May support aspirin thromboprophylaxis after hip arthroplasty; leaves open confirmation in randomized trials.
Cohort (n=4,204)
Does aspirin monotherapy prevent fatal pulmonary embolism, all-cause mortality, and VTE compared to enoxaparin or warfarin in patients following total hip arthroplasty?
p-value: p=0.780 for mortality, 1 for VTE
Aspirin monotherapy is an effective and safe standard thromboprophylactic agent following total hip arthroplasty, with no increased mortality or VTE compared to enoxaparin or warfarin.
Borton et al. (2021) conducted a cohort in Total hip arthroplasty (n=4,204). Aspirin vs. Enoxaparin and warfarin was evaluated on 90-day all-cause mortality and venous thromboembolism (VTE) (p=0.780 for mortality, 1 for VTE). Aspirin thromboprophylaxis following total hip arthroplasty was associated with similar 90-day all-cause mortality (p=0.780) and venous thromboembolism (p=1) compared to enoxaparin and warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: